Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.
Objective: To report COVID-19 rates in pwMS according to vaccine serology.
Methods: PwMS with available (1) serology 2-12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included. Logistic regression was performed to examine whether seroconversion following vaccination predicted risk of subsequent COVID-19 infection after adjusting for potential confounders. Rates of severe COVID-19 (requiring hospitalisation) were also calculated.
Results: A total of 647 pwMS were included (mean age 48 years, 500 (77%) female, median Expanded Disability Status Scale (EDSS) 3.5% and 524 (81%) exposed to DMT at the time of vaccine 1). Overall, 472 out of 588 (73%) were seropositive after vaccines 1 and 2 and 222 out of 305 (73%) after vaccine 3. Seronegative status after vaccine 2 was associated with significantly higher odds of subsequent COVID-19 infection (odds ratio (OR): 2.35, 95% confidence interval (CI): 1.34-4.12, = 0.0029), whereas seronegative status after vaccine 3 was not (OR: 1.05, 95% CI: 0.57-1.91). Five people (0.8%) experienced severe COVID-19, all of whom were seronegative after most recent vaccination.
Conclusion: Attenuated humoral response to initial COVID-19 vaccination predicts increased risk of COVID-19 in pwMS, but overall low rates of severe COVID-19 were seen.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333979 | PMC |
| http://dx.doi.org/10.1177/13524585231185247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.
BMC Glob Public Health
September 2025
Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Background: Between November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km).
Methods: We analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms.
Correction: Altered immune surveillance of B and T cells in patients with persistent residual lung abnormalities 12 months after severe COVID-19.
Respir Res
September 2025
Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, Mexico.
Sensitive and specific affinity purification-mass spectrometry assisted by PafA-mediated proximity labeling.
Cell Rep Methods
September 2025
Lingang Laboratory, Shanghai 201306, China. Electronic address:
While affinity purification-mass spectrometry (AP-MS) has significantly advanced protein-protein interaction (PPI) studies, its limitations in detecting weak, transient, and membrane-associated interactions remain. To address these challenges, we introduced a proteomic method termed affinity purification coupled proximity labeling-mass spectrometry (APPLE-MS), which combines the high specificity of Twin-Strep tag enrichment with PafA-mediated proximity labeling. This method achieves improved sensitivity while maintaining high specificity (4.
View Article and Find Full Text PDFA bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.
Vaccine
September 2025
College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; Hubei Jiangxia Laboratory, Wuhan 430200, China. Electronic address:
The spillover and spillback of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between humans and animals, especially companion animals, threaten global public health security. However, risk assessment of SARS-CoV-2 variants infecting companion animals and the development of corresponding prevention and control technologies are lacking. The aim of this study is to assess the potential risk of enhancement of the infectivity of SARS-CoV-2 in cats owing to mutations at key sites within the spike (S) protein receptor-binding domain (RBD) region and develop an efficient vaccine to cross-neutralize high-risk SARS-CoV-2 variants.
View Article and Find Full Text PDFBovine coronavirus Nsp14 protein promotes viral replication by degrading TRAF3 to inhibit interferon production.
Vet Microbiol
September 2025
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China; Shanghai Key Laboratory of Veterinary Biotechnology, Shanghai 200240, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou Unive
Bovine coronavirus (BCoV), a member of the Betacoronavirus genus, causes severe calf gastroenteritis and respiratory disease, resulting in a significant loss of livestock. Coronavirus non-structural protein 14 (nsp14) is involved in viral RNA replication and modification and subverts host immune regulatory pathways to facilitate immune evasion. In this study, we demonstrated that BCoV nsp14 mediates TNF receptor-associated factor 3 (TRAF3) degradation through the coordinated targeting of the ubiquitin-proteasome and autophagy-lysosomal pathways, thereby potentiating viral replication.
View Article and Find Full Text PDF